STAAR Surgical Company Cash Flow Conversion Efficiency
STAAR Surgical Company cash flow conversion efficiency. Based on the latest financial reports, STAAR Surgical Company (STAA) has a cash flow conversion efficiency ratio of 0.054x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($19.69 Million) by net assets ($365.40 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of STAAR Surgical Company (1990–2025)
Cash flow conversion efficiency of STAAR Surgical Company from 1990 to 2025. This chart illustrates how STAAR Surgical Company's cash flow conversion efficiency has evolved over time, based on yearly financial data. View STAAR Surgical Company share price for real-time trading data and today's change.
STAAR Surgical Company Cash Flow Conversion Ratio Explained
STAAR Surgical Company cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
STAAR Surgical Company Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of STAAR Surgical Company ranked by their cash flow conversion efficiency. Also see STAA stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Edelweiss Financial Services Limited
NSE:EDELWEISS
|
-0.118x |
|
CVR Partners LP
NYSE:UAN
|
0.190x |
|
KSB Ltd
NSE:KSB
|
0.019x |
|
Grupo Televisa S.A.B
MX:TLEVISACPO
|
0.100x |
|
Hubei Jianghan New Materials Co. Ltd. A
SHG:603281
|
N/A |
|
HuBei SanFeng Intelligent Conveying Equipment Co Ltd
SHE:300276
|
0.100x |
|
Shenyang Xingqi Pharmaceutical Co Ltd
SHE:300573
|
0.145x |
|
Nabors Industries Ltd
F:NBI1
|
0.079x |
Annual Cash Flow Conversion Efficiency for STAAR Surgical Company (1990–2025)
The table below shows the annual cash flow conversion efficiency of STAAR Surgical Company from 1990 to 2025. Review STAA FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $344.18 Million | $-34.23 Million | -0.099x | -351.29% |
| 2024-12-31 | $397.33 Million | $15.72 Million | 0.040x | +4.66% |
| 2023-12-31 | $385.95 Million | $14.59 Million | 0.038x | -64.41% |
| 2022-12-31 | $336.11 Million | $35.72 Million | 0.106x | -37.50% |
| 2021-12-31 | $258.56 Million | $43.96 Million | 0.170x | +60.06% |
| 2020-12-31 | $197.22 Million | $20.95 Million | 0.106x | -34.16% |
| 2019-12-31 | $159.88 Million | $25.80 Million | 0.161x | +67.35% |
| 2018-12-31 | $132.43 Million | $12.77 Million | 0.096x | +45.09% |
| 2017-12-31 | $42.94 Million | $2.85 Million | 0.066x | +140.10% |
| 2016-12-31 | $37.91 Million | $1.05 Million | 0.028x | +149.72% |
| 2015-12-31 | $38.85 Million | $-2.16 Million | -0.056x | +74.03% |
| 2014-12-31 | $37.10 Million | $-7.95 Million | -0.214x | -348.41% |
| 2013-12-31 | $38.85 Million | $3.35 Million | 0.086x | -14.87% |
| 2012-12-31 | $31.74 Million | $3.22 Million | 0.101x | -44.15% |
| 2011-12-31 | $29.46 Million | $5.35 Million | 0.181x | +192.14% |
| 2010-12-31 | $22.43 Million | $-4.42 Million | -0.197x | -390.80% |
| 2009-12-31 | $21.07 Million | $1.43 Million | 0.068x | +113.19% |
| 2008-12-31 | $16.03 Million | $-8.23 Million | -0.513x | -66.29% |
| 2007-12-31 | $36.23 Million | $-11.18 Million | -0.309x | -13.40% |
| 2006-12-31 | $31.76 Million | $-8.65 Million | -0.272x | -57.54% |
| 2005-12-31 | $40.37 Million | $-6.98 Million | -0.173x | +25.68% |
| 2004-12-31 | $37.86 Million | $-8.80 Million | -0.233x | -98.67% |
| 2003-12-31 | $35.42 Million | $-4.15 Million | -0.117x | -730.49% |
| 2002-12-31 | $30.65 Million | $569.00K | 0.019x | +133.98% |
| 2001-12-31 | $46.83 Million | $-2.56 Million | -0.055x | +40.35% |
| 2000-12-31 | $58.67 Million | $-5.37 Million | -0.092x | -199.42% |
| 1999-12-31 | $53.20 Million | $4.90 Million | 0.092x | +4.10% |
| 1998-12-31 | $48.60 Million | $4.30 Million | 0.088x | -47.84% |
| 1997-12-31 | $44.80 Million | $7.60 Million | 0.170x | -26.95% |
| 1996-12-31 | $36.60 Million | $8.50 Million | 0.232x | +33.31% |
| 1995-12-31 | $28.70 Million | $5.00 Million | 0.174x | -4.18% |
| 1994-12-31 | $22.00 Million | $4.00 Million | 0.182x | +318.18% |
| 1993-12-31 | $12.00 Million | $-1.00 Million | -0.083x | +80.38% |
| 1992-12-31 | $7.30 Million | $-3.10 Million | -0.425x | +62.73% |
| 1991-12-31 | $4.30 Million | $-4.90 Million | -1.140x | -13.95% |
| 1990-12-31 | $100.00K | $-100.00K | -1.000x | -- |
About STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorde… Read more